Related trials
TRIANA, 2009 - primary ballon angioplasty vs tenecteplase
DEBATER (SES vs BMS), 2009 - sirolimus eluting stent vs bare-metal stent
NORDISTEMI, 2009 - thrombolysis + angioplasty vs immediate thrombolysis
Juwana, 2009 - sirolimus eluting stent vs paclitaxel eluting stent
ZEST AMI (vs PES), 2009 - zotarolimus eluting stent vs paclitaxel eluting stent
PASEO, 2009 - drug-eluting stents vs bare-metal stent
ZEST AMI (vs SES), 2009 - zotarolimus eluting stent vs sirolimus eluting stent
CARESS, 2008 - thrombolysis + angioplasty vs immediate thrombolysis
HORIZONS-AMI Stent, 2008 - paclitaxel eluting stent vs bare-metal stent
MISSION, 2008 - sirolimus eluting stent vs bare-metal stent
DEDICATION, 2008 - drug-eluting stents vs bare-metal stent
D�az de la Llera, 2007 - sirolimus eluting stent vs bare-metal stent
SESAMI, 2007 - sirolimus eluting stent vs bare-metal stent
PROSIT, 2006 - sirolimus eluting stent vs paclitaxel eluting stent
HAAMU-STENT, 2006 - paclitaxel eluting stent vs bare-metal stent
PASSION, 2006 - paclitaxel eluting stent vs bare-metal stent
WEST, 2006 - systematic PCI (+stent) vs no systematic PCI
TYPHOON, 2006 - sirolimus eluting stent vs bare-metal stent
ZWOLLE 6, 2005 - primary stenting vs balloon angioplasty
CAPITAL AMI, 2005 - systematic PCI (+stent) vs no systematic PCI
senior PAMI, 2005 - primary PCI vs Thrombolysis
CAPITAL AMI, 2005 - thrombolysis + angioplasty vs immediate thrombolysis
Di Lorenzo et al., 2005 - sirolimus eluting stent vs paclitaxel eluting stent
GRACIA-1, 2004 - systematic PCI (+stent) vs no systematic PCI
MERLIN (Sutton), 2004 - immediate systematic ballon angioplastyte vs no immediate angioplasty
See also:
All acute myocardial infarction clinical trials
All clinical trials of PCI
All clinical trials of thrombolysis + angioplasty
|
|
Treatments
Studied treatment |
transfer for immediate coronary angiography and intervention
|
Control treatment |
concervative strategy
ischemia-guided treatment in local hospitals with transfer for rescue PCI if needed
|
Concomittant treatment |
optimal medical therapy (tenecteplase, aspirin 300 mg, enoxaparin 30 mg iv 1mg/kg sc, clopidogrel 300 mg |
Patients
Patients |
patients with STEMI of less than 6 hours of duration and more than 90 minutes expected time delay to PCI |
Method and design
Randomized effectives |
134 / 132 (studied vs. control) |
Design |
Parallel groups |
Blinding |
open |
Follow-up duration |
1y |
Geographic area |
Norway |
Primary endpoint |
death, reMI, stroke, new ischaemia |
Results
Endpoint
Studied treat. n/N
Control treat. n/N
Graph
RR [95% CI]
death, reinfarctus, stroke
NA / 134
NA / 132
0,36 [0,16;0,81]
0
2
1.0
Relative risks
|
Endpoint |
Events (%) |
Relative Risk |
95% CI |
Endpoint definition in the trial |
Ref |
Studied treat. |
Control treat. |
The primary endpoint (if exists) appears in blod characters
|
Reference(s) used for data extraction:
|
Endpoint |
studied treat. |
control treat. |
mean diff |
Absolute risk reduction
|
Endpoint |
Events rate |
Absolute risk reduction (ARR) |
Studied treat. |
Control treat. |
Meta-analysis of all similar trials:
myocardial revascularization in acute myocardial infarction for all type of patients
PCI in acute myocardial infarction for all type of patients
Reference(s)
|